Moderna Stock Soaring: Is It Still Worth Buying Now?
Moderna stock has surged on vaccine optimism and pipeline potential. This guide breaks down what’s behind the move, w...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
134 articles
Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Fidelity Health Care State: Which ETF Fits Your Portfolio Best
Choosing between broad healthcare exposure and biotech specificity can shape a portfolio for years. This guide breaks...
How Much Could $1,000 Invested in Viking Grow by 2030?
Investing in biotech can be bold. This piece lays out practical scenarios for what much could $1,000 invested in Viki...
Vanguard Health Care ISHARES: How They Stack Up for Modern Portfolios
A clear look at how Vanguard Health Care and iShares Biotechnology compete for space in a diversified portfolio. Lear...
FHLC BBH: Which Healthcare ETF Is Best for Your Portfolio?
Healthcare investing offers breadth and specialty. This guide explains FHLC and BBH, how they differ, and how to deci...
Biogen Paying Billion Company Signals BIIB Turnaround
Biogen’s $1 billion move on a mystery company has investors buzzing. This article breaks down why the deal could be a...
Pfizer's Says Company "Very" Big Balance Sheet for Deals
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
Three Factors That Have Brought Small-Cap Trade to Life
A revival in small-cap stocks is taking shape as three key forces converge. AI-driven demand, a steadier macro backdr...
Wall Street Thinks This Biotech Stock Could Soar 57%
Biotech investing often rides on data, not on dreams. This educational piece uses a fictional company to show how wal...
Lilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...